UCB Ventures is a venture capital arm of UCB, a global biopharmaceutical company. It invests in innovative therapeutics and technology platforms.

UCB Ventures

UCB Ventures is the strategic corporate venture fund of UCB Pharma.
Our mission is to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. 
We make long term investments in early stage companies in the US and Europe. 

We are known for our speed and agility, yet thoughtful and sophisticated approach. Above all, we are committed investors, working closely with entrepreneurs to bring out the best in our portfolio companies.

Investment strategy:
We invest in start-ups developing novel therapeutic modalities, platforms/assets that address novel biology, or innovative digital solutions, in areas adjacent to or even beyond UCB's current therapeutic focus. 
We are seeking breakthrough innovations that enable modulation of genetic systems and/or restore cell and tissue homeostasis in the context of disease. 
We consider all therapeutic modalities and are indication agnostic for all platforms.

Syndesi Therapeutics

If you are attending #BioEquityEurope2024, come and meet our CEO, Miquel Vila-Perello and CBO, Gerard Caelles, next week in San Sebastian! 
 
Join Miquel on 13 May, where he will participate on a panel, titled ‘Scaling Up Europe’s Academic Engine in Cell and Gene Therapy' where he will provide his thoughts on the current cell and gene therapy landscape at 11:15 CEST.
 
At 15:45 CEST on 13 May, Miquel will present 🎤 on SpliceBio's proprietary Protein Splicing platform and lead #GeneTherapy program, SB007, where he will provide an update on the Company's latest developments.
 
Schedule a 1-1 meeting with the team at BioEquity via the online partnering portal here https://bit.ly/3JJQ0r1 or reach out directly via LinkedIn.
 
Revolutionizing genetic medicine with its proprietary Protein Splicing platform!
 
#biotech #retinaldiseases #lifesciences #ProteinSplicing #genetherapy

We are pleased to announce that our CMO, Aniz Girach, is presenting at the Retinal Cell and Gene Therapy Innovation Summit today! 
 
If you are attending the event, make sure to see Aniz's presentation, titled 'Intein-based dual-AAV gene therapy for Stargardt disease', from 09:50 – 10:05 PDT.
 
Get in touch to arrange a meeting with the team and find out more about SpliceBio's lead #genetherapy program targeting #Stargardtdisease.
 
#biotech #retinaldiseases #lifesciences

Meet us at BioEquity Europe 2024 from 12-14 May in San Sebastian, where our CSO Viki Bockstal, and our Chair of the Board, Jeanne Bolger, are attending.

Viki will be presenting about what we’re doing in the fight against #infectiousdiseases, including #Covid19 and #Dengue, with our highly potent heavy chain-only antibodies. 

Our pipeline addresses the strong societal need for novel antibodies that can protect even the most vulnerable populations, including elderly and immunocompromised, and can be an integral part of pandemic preparedness strategies.

🤝 Request a partnering meeting now: https://lnkd.in/eaw_6uwz

🔬 Learn about our unique heavy chain-only antibody technology and latest research: https://lnkd.in/etaU9RJk

🔗 Join #BioEquity Europe 2024: https://lnkd.in/dzunkQc

#Pharma #Biotech #Networking

We couldn't be more excited for our upcoming move to Unity Campus and to contribute to the growing community on this fantastic, emerging biomedical campus!

🎉 Experienced company builder David Hipkiss joins us as Independent Chair at a pivotal time - we're preparing to start clinical trials with our lead #hearingloss product Rincell-1. 
 
👨🏼‍💻 His extensive experience in business development and fundraising in both private and public company settings will greatly benefit Rinri Therapeutics. David Hipkiss is also Executive Chair at respiratory gene therapy company AlveoGene. 
 
👂Using its proprietary #OSPREY™ platform, Rinri Therapeutics is developing a portfolio of off-the-shelf #regenerative cell therapy products designed to address sensorineural hearing loss, a significant global medical challenge. 
 
For the full press release please go to: https://bit.ly/3UlBdc1
 
#celltherapy UCB Ventures Boehringer Ingelheim Pioneer Group

Metric
Company Name	UCB Ventures
Symbol
MSH ID	COM:UCBVENTURES
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital
Country	BE
Stage
Employee Count	1
Website	ucbventures.com
LinkedIn	ucb-ventures
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

UCBV

COM:UCBVENTURES

UCB Ventures

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue